175 related articles for article (PubMed ID: 35101947)
1. A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
[TBL] [Abstract][Full Text] [Related]
2. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
3. IL-15 in the Combination Immunotherapy of Cancer.
Waldmann TA; Dubois S; Miljkovic MD; Conlon KC
Front Immunol; 2020; 11():868. PubMed ID: 32508818
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
5. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
6. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
Zhang M; Yao Z; Dubois S; Ju W; Müller JR; Waldmann TA
Proc Natl Acad Sci U S A; 2009 May; 106(18):7513-8. PubMed ID: 19383782
[TBL] [Abstract][Full Text] [Related]
8. IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.
Chen W; Bamford RN; Edmondson EF; Waldmann TA
Clin Cancer Res; 2022 May; 28(10):2082-2093. PubMed ID: 35262675
[TBL] [Abstract][Full Text] [Related]
9. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages.
Zhang M; Wen B; Anton OM; Yao Z; Dubois S; Ju W; Sato N; DiLillo DJ; Bamford RN; Ravetch JV; Waldmann TA
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10915-E10924. PubMed ID: 30373815
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink.
Hangasky JA; Waldmann TA; Santi DV
Front Immunol; 2020; 11():1813. PubMed ID: 32903632
[TBL] [Abstract][Full Text] [Related]
11. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
12. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
[TBL] [Abstract][Full Text] [Related]
13. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
[TBL] [Abstract][Full Text] [Related]
14. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
Ciavarra RP; Holterman DA; Brown RR; Mangiotti P; Yousefieh N; Wright GL; Schellhammer PF; Glass WF; Somers KD
J Immunother; 2004; 27(1):13-26. PubMed ID: 14676630
[TBL] [Abstract][Full Text] [Related]
15. Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8
Shimizu K; Ueda S; Kawamura M; Aoshima H; Satoh M; Nakabayashi J; Fujii SI
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37400134
[TBL] [Abstract][Full Text] [Related]
16. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood.
Sneller MC; Kopp WC; Engelke KJ; Yovandich JL; Creekmore SP; Waldmann TA; Lane HC
Blood; 2011 Dec; 118(26):6845-8. PubMed ID: 22067383
[TBL] [Abstract][Full Text] [Related]
17. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.
Han BJ; Murphy JD; Qin S; Ye J; Uccello TP; Garrett-Larsen J; Belt BA; Prieto PA; Egilmez NK; Lord EM; Linehan DC; Mills BN; Gerber SA
Immunol Invest; 2020 Oct; 49(7):808-823. PubMed ID: 32498585
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-15 in cancer immunotherapy: IL-15 receptor complex versus soluble IL-15 in a cancer cell-delivered murine leukemia model.
Berger A; Colpitts SJ; Seabrook MSS; Furlonger CL; Bendix MB; Moreau JM; McKillop WM; Medin JA; Paige CJ
J Immunother Cancer; 2019 Dec; 7(1):355. PubMed ID: 31856922
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
20. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.
Sato N; Sabzevari H; Fu S; Ju W; Petrus MN; Bamford RN; Waldmann TA; Tagaya Y
Blood; 2011 Apr; 117(15):4032-40. PubMed ID: 21304101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]